References
1. Choudhary S, Sreenivasulu K, Mitra P, Misra S, Sharma P. Role of Genetic Variants and Gene Expression in the Susceptibility and Severity of COVID-19. Ann Lab Med. 2021;41(2):129-138.
2. Bontempi E. The europe second wave of COVID-19 infection and the Italy ”strange” situation. Environ Res. 2021;193:110476.
3. Bakhshandeh B, Sorboni SG, Javanmard AR, et al. Variants in ACE2; potential influences on virus infection and COVID-19 severity.Infect Genet Evol. 2021;90:104773.
4. Zhao S, Lou J, Cao L, et al. Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the United Kingdom: An early data-driven analysis. J Travel Med. 2021.
5. Yi C, Sun X, Ye J, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol. 2020;17(6):621-630.
6. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin.2020;41(9):1141-1149.
7. Bachmann MF, Zinkernagel RM. The influence of virus structure on antibody responses and virus serotype formation. Immunol Today.1996;17(12):553-558.
8. Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv. 2021.
9. Petersen RL. Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development. Biosensors (Basel). 2017;7(4).
10. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.Nat Med. 2021.
11. Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv.2021.
12. Greaney AJ, Starr TN, Gilchuk P, et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe. 2021;29(1):44-57 e49.
13. Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv.2020.
14. Rathnasinghe R, Jangra S, Cupic A, et al. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera.medRxiv. 2021.
15. Corum J, Zimmer C. Coronavirus variants and mutations. The New York Times. March 22, 2021, 2021.
16. News B. Coronavirus infection levels continue to drop in the UK. In. 5 March ed2021.
17. Candido DS, Claro IM, de Jesus JG, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science.2020;369(6508):1255-1260.
Table 1 Kinetic parameters of RBDWT and mutated RBDs calculated by BLI